How Analysts Feel About Sangamo Therapeutics, Inc. (SGMO) After Today’s Huge Increase?

April 17, 2018 - By Ellis Scott

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Investors sentiment decreased to 1.4 in 2017 Q4. Its down 0.17, from 1.57 in 2017Q3. It dropped, as 16 investors sold Sangamo Therapeutics, Inc. shares while 42 reduced holdings. 35 funds opened positions while 46 raised stakes. 53.22 million shares or 2.49% more from 51.93 million shares in 2017Q3 were reported.
Great West Life Assurance Can holds 0% or 12,767 shares. Commercial Bank Of Montreal Can reported 9,679 shares or 0% of all its holdings. Gp One Trading Ltd Partnership invested in 241,729 shares or 0.03% of the stock. Legal & General Grp Public Limited Liability Company holds 21,358 shares. Rhumbline Advisers stated it has 79,032 shares or 0% of all its holdings. Macquarie Group Incorporated Ltd holds 20,100 shares. State Street Corp holds 3.98 million shares or 0.01% of its portfolio. Ameritas Inv Prtn holds 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 7,067 shares. Alliancebernstein L P reported 190,583 shares stake. Cornerstone Capital Mgmt Ltd Liability holds 43,200 shares. Barclays Plc holds 0% or 80,885 shares. Pub Employees Retirement Association Of Colorado reported 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Guggenheim Limited Co accumulated 0% or 128,715 shares. Stratos Wealth Ptnrs Limited reported 0% stake. Aperio Group Ltd Company has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO).

Since January 2, 2018, it had 0 insider buys, and 13 sales for $2.30 million activity. Another trade for 9,433 shares valued at $219,546 was made by Mento Steven J on Thursday, March 1. Another trade for 5,000 shares valued at $85,545 was sold by Conner Edward R.. Ramasastry Saira also sold $235,080 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares. Yi Kathy also sold $127,812 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares.

The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is a huge mover today! The stock increased 9.08% or $1.625 during the last trading session, reaching $19.525. About 1.77M shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since April 17, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.
The move comes after 8 months positive chart setup for the $1.69B company. It was reported on Apr, 17 by Barchart.com. We have $20.70 PT which if reached, will make NASDAQ:SGMO worth $101.16M more.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on May, 9. They expect $0.05 earnings per share, up 121.74 % or $0.28 from last year’s $-0.23 per share. SGMO’s profit will be $4.32 million for 97.63 P/E if the $0.05 EPS becomes a reality. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -133.33 % EPS growth.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Among 7 analysts covering Sangamo Therapeutics (NASDAQ:SGMO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Sangamo Therapeutics had 9 analyst reports since November 15, 2017 according to SRatingsIntel. As per Thursday, February 22, the company rating was maintained by Wells Fargo. As per Thursday, February 22, the company rating was maintained by Piper Jaffray. The rating was maintained by Wedbush with “Hold” on Tuesday, March 13. PiperJaffray upgraded the stock to “Overweight” rating in Wednesday, November 15 report. On Wednesday, January 3 the stock rating was maintained by Piper Jaffray with “Buy”. On Wednesday, November 15 the stock rating was maintained by Wedbush with “Hold”. The stock has “Buy” rating by Jefferies on Thursday, February 22.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.69 billion. The company??s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: